Nuvectis Pharma ratios data for the quarter ended Jun 2026. These financial ratios cover 18 quarters of results from Mar 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Efficiency | ||||||||||||||||||
| Assets AverageAssets Avg. | 12.14M | 15.93M | 19.55M | 22.64M | 18.31M | 20.57M | 23.60M | 20.72M | 19.45M | 19.01M | 17.80M | 17.96M | 24.38M | 28.58M | 31.30M | 33.65M | 28.55M | 23.89M |
| Valuation | ||||||||||||||||||
| Price to EarningsP/E | -23.06 | -39.91 | -17.66 | -14.18 | -51.83 | -48.18 | -37.94 | -21.94 | -36.09 | -26.80 | -28.75 | -16.88 | -43.31 | -28.16 | -15.61 | -26.51 | -33.89 | -69.93 |
| Price to BookP/B | 4.66 | 12.39 | 5.10 | 6.68 | 17.10 | 13.53 | 13.37 | 11.91 | 10.73 | 9.47 | 10.87 | 10.86 | 11.02 | 10.57 | 6.43 | 10.53 | 14.42 | 54.05 |
| Enterprise Value | 51.17M | 128.84M | 80.18M | 74.94M | 194.36M | 250.42M | 201.02M | 126.15M | 131.02M | 100.56M | 102.22M | 86.94M | 201.01M | 151.57M | 118.91M | 162.23M | 179.91M | 468.72M |
| EV to EBIT | -17.37 | -36.06 | -13.50 | -11.06 | -47.39 | -43.39 | -32.64 | -18.37 | -29.80 | -21.66 | -23.45 | -13.48 | -36.10 | -22.98 | -15.26 | -21.30 | -28.74 | -65.13 |
| EV to EBITDA | -17.37 | -36.06 | -13.50 | -11.06 | -47.39 | -43.39 | -32.64 | -18.37 | -29.80 | -21.66 | -23.45 | -13.48 | -36.10 | -22.98 | -15.26 | -21.30 | -28.74 | -65.13 |
| Market Capitalization | 67.87M | 142.44M | 103.82M | 94.93M | 209.86M | 275.02M | 223.12M | 145.27M | 150.52M | 118.68M | 119.42M | 105.47M | 230.91M | 178.37M | 154.35M | 193.86M | 205.04M | 490.92M |
| Price to FCFP/FCF | -22.06 | -56.01 | -23.47 | -27.00 | -43.93 | -67.36 | -68.78 | -37.73 | -34.54 | -39.30 | -49.67 | -42.79 | -55.32 | -52.97 | -34.35 | -48.78 | -31.49 | -108.35 |
| EV to FCF | -16.63 | -50.66 | -18.12 | -21.31 | -40.69 | -61.33 | -61.97 | -32.77 | -30.06 | -33.30 | -42.52 | -35.27 | -48.16 | -45.02 | -26.46 | -40.82 | -27.63 | -103.45 |
| EV to CFO | -16.63 | -50.66 | -18.12 | -21.31 | -40.69 | -61.33 | -61.97 | -32.77 | -30.06 | -33.30 | -42.52 | -35.27 | -48.16 | -45.02 | -26.46 | -40.82 | -27.63 | -103.45 |
| Return Ratios | ||||||||||||||||||
| Return on Capital Employed [ROCE]ROCE | -174.21% | -101.98% | -97.75% | -116.93% | -141.87% | -141.49% | -126.54% | -166.65% | -168.58% | -166.69% | -176.42% | -218.99% | -138.43% | -124.55% | -133.90% | -135.49% | -162.68% | -272.52% |
| Return on Assets [ROA]ROA | -130.29% | -84.41% | -74.95% | -84.31% | -110.29% | -108.53% | -94.63% | -107.41% | -115.08% | -111.03% | -108.83% | -105.81% | -82.70% | -77.22% | -81.08% | -78.58% | -95.12% | -116.57% |